[Impact of Home Return Assistance Service in Heart Failure (PRADO-IC) on the one year re-hospitalisation and mortality in a heart failure hospitalized population of patients].
Impact du programme d'aide au retour à domicile-insuffisance cardiaque (PRADO-IC) sur la mortalité et la réhospitalisation à un an dans une population de patients insuffisants cardiaques.
Health education programs
Heart failure
Patient education as a subject
Journal
Annales de cardiologie et d'angeiologie
ISSN: 1768-3181
Titre abrégé: Ann Cardiol Angeiol (Paris)
Pays: France
ID NLM: 0142167
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
05
07
2022
accepted:
16
07
2022
pubmed:
9
8
2022
medline:
29
11
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Congestive heart failure (CHF) is associated with prolonged and recurrent hospitalizations; the prognosis remains poor. Since 2013, the Caisse Primaire d'Assurance Maladie (CPAM) has set up a support program PRADO-IC (support program for returning home after hospitalisation for heart failure). The aim of this study was to evaluate the impact of PRADO-IC on the heart failure readmission rate and death rate at one year. From September 2016 to September 2018, all patients hospitalized for heart failure at Saint-Joseph Hospital were included in an observational study. The inclusion in PRADO-IC program was at physician's discretion. Two groups were compared according to the inclusion in PRADO-IC or not (T). The primary endpoints were the comparison of one-year mortality and heart failure readmission rate between the two groups. Six hundred and thirty-three patients were included, 262 in the PRADO-IC group and 371 in the non-PRADO group. Patients in the PRADO-IC cohort more frequently present severity criteria (age, weight, BNP level, arrhythmia, anemia, renal failure). Mortality at one year (19.5% vs 16.2%, p = 0.28) are equivalent in both groups. There were no significant differences in one-year rehospitalization rate for heart failure (HF) (35.1% in PRADO cohort vs 28% in T group, p = 0.06), the time to first hospitalization (74.5 days in PRADO vs 54.5 days in T, p = 0.55) and the length of hospitalization (6.0 days in PRADO vs 7.0 days in T, p = 0.29) between the two groups. Age, hyponatremia, anemia, cancer, HF re-hospitalization were variables linked to a risk of mortality, in a multivariable analysis. Our study shows that the PRADO-IC program concerned to the most severe patients. Despite this, the one-year mortality and the HF readmission rate are similar between the two groups.
Identifiants
pubmed: 35940973
pii: S0003-3928(22)00113-5
doi: 10.1016/j.ancard.2022.07.004
pii:
doi:
Types de publication
Observational Study
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
267-275Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.